Over 20 Chinese Biopharma Companies to Showcase Innovations at J.P. Morgan Healthcare Conference 2026

Jan 12, 2026 07:51 CST Updated 07:51

BeOne

Developer of Molecular Targeted and Immune Anti-Tumor Drugs

Zai Lab

Innovative Global Biopharmaceutical Company

Legend Biotech

Tumor Cell Immunotherapy Developer

Johnson & Johnson

Medical Device R&D and Manufacturer

The 44th Annual J.P. Morgan Healthcare Conference(abbreviation: JPM Conference) will be held onLocal timeJanuary 12-15, 2026Grandly held in San Francisco, USA.

According to the schedule published on the JPM Conference official website, there are over20 Chinese CompaniesWill attend this conference and deliver a speech.This article will briefly introduceInformation on Some Chinese Innovative Pharmaceutical Companies Presented at This Year's JPM Conference, for readers' reference only.

Screenshot source: JPM Conference Agenda

CompanyName: BeOne Medicines

Presentation Time: January 13, 7:30 am PST

BeOne Medicines is a global oncology innovation company dedicated to developing innovative anti-cancer drugs for cancer patients worldwide.According to the Insight database, BeOne Medicines currently has 14 new drugs approved for marketing, four of which were self-developed, namelyTislelizumab（PD-1 Inhibitor）、Zanubrutinib（BTK Inhibitor）、Pamiparib（PARP Inhibitor）AndSotoclax（BCL2 Inhibitor）。

Screenshot source: Insight database

2025In the first three quarters, BeOne Medicines' revenue reached27.595 billion yuan, a year-on-year increase of 44.2%, surpassing last year's total revenue of 27.21 billion yuan, of whichZanubrutinib sales have reachedRMB 19.95 billion。BeOne MedicinesIt is estimated that the total revenue for 2025 in China will beBetween RMB 36.2 billion and RMB 38.1 billion。

CompanyName: Zai Lab

Speech Time:Pacific Ocean, United StatesTime: January 13th, 3:00 pm

Zai Lab was founded in 2014 and is committed to providing patients with best-in-class and first-in-class therapies for oncology, immunology, neuroscience, and infectious diseases. Insight database shows that Zai Lab currently has, includingUsed forSchizophreniaFirst-in-class drugsTropsium ChlorideFirst FcRn AntagonistEfgartigimod,World's First Cervical Cancer ADC DrugSeveral重磅new drugs, such as Vutrisotug, have been approved for marketing, all of which are引进的.

Screenshot source: Zai Lab official website

In addition to introducing products, Zai Lab has also been expanding its self-developed projects in recent years and already hasThree Innovative Products Enter Clinical Stage, respectivelyCCR8 Monoclonal AntibodyZL-1218、CD47 Monoclonal AntibodyZL-1201 andIL-13/IL-31R Bispecific Antibody ZL-1503。

Company Name: Legend Biotech

Speech Time: Pacific Time (US)Time: January 14, 9:00 am

Legend Biotech was founded in 2014 and mainly focuses on tumor immunotherapy.According to the Insight database, Legend Biotech currently has only one approved product on the market, which is the CAR-T therapy co-developed with Johnson & Johnson.Cilta-cel.In the first three quarters of 2025, the global sales of the drug reached USD 1.332 billionLegend Biotech expects to achieve within the year.Profitability, thereby driving the company to achieve overall profitability by 2026.

Screenshot source: Legend Biotech official website

Except forIn addition to Cilta-cel, Legend Biotech has 22 new drugs entering the clinical stage.(Only active status is counted), including the universal CAR-γδT cell therapy targeting dual CD20/CD19 sites, Lucar-G39D, and the collaboration with Novartis.CAR-T Therapy Specifically Targeting DLL3LB2102 etc.

Company Name: Ascentage Pharma

Speech Time:Pacific Ocean, United StatesTime: January 14, 2:15 pm

Ascentage Pharma was founded in 2009, primarily focusing on the development of innovative drugs in the field of oncology.Listed on the Main Board of the Hong Kong Stock Exchange on October 28, 2019, and listed on NASDAQ in the United States on January 24, 2025.

Currently, Ascentage Pharma has established a rich pipeline of innovative drugs, including inhibitors targeting key proteins in the apoptosis pathway such as Bcl-2 and MDM2-p53, as well as next-generation inhibitors against kinase mutants that emerge during cancer treatment.

Screenshot source: Ascentage Pharma official website

According to the Insight database, Ascentage Pharma has already had 2 products approved for marketing, one of which isThe First Approved in ChinaThe Third Generation BCR-ABL InhibitorOrelabrutinib, another one isChina's First Domestically Produced Bcl-2 InhibitorRisankizumab.

Company Name: 3SBio

Speech Time:Pacific Ocean, United StatesTime: January 15th, 8:00 am

3SBio is a biopharmaceutical company that integrates research and development, production, and sales.With more than 40 marketed products covering various therapeutic areas such as nephrology, oncology, autoimmune diseases, ophthalmology, and dermatology.

According to the Insight database, as of now,3SBio has 5 new drugs in the marketing review stage, includingIL-17A Innovative Monoclonal Antibody SSGJ-608、IL-1β Monoclonal Antibody SSGJ-613、Bevacizumab Intravitreal Injection Solution 601A, etc. In addition, there are 5 products that have advanced to Phase III clinical trials.

Screenshot source: Insight database

In 2025, 3SBio completed 2 BD deals, one of which was granting PfizerPD-1/VEGF Bispecific AntibodySSGJ-707 Global Development and Commercialization Rights; another isAcquired Duality BiologicsHER2 ADC Commercialization rights for multiple indications of the drug DB-1303 in mainland China, Hong Kong, and Macao.

Company Name:Rongchang Bio

Speech Time:Pacific Ocean, United StatesTime: January 15th, 9:00 am

Rongchang Bio was founded in 2008,Focus on R&DADC, Antibody Fusion Proteins, Monoclonal Antibodies, and Bispecific AntibodiesInnovative biologics,Focusing on major disease areas such as autoimmune diseases, oncology, and ophthalmology.

Currently, Rongchang Bio hasTelitacip, VidicimabTwo products have been approved for marketing, and there is also one more.ForVEGF/FGF Dual-Target Fusion Protein for Ocular Neovascular DiseasesDrug RC28-ECurrently under the review stage for market approval. In addition, Rongchang Biotech hasHeavyweight products such as PD-1/VEGF bispecific antibody and MSLN ADC have entered the clinical stage.

Source of screenshot:Insight Database

Company Name: Kelun Botai

Speech Time:Pacific Ocean, United StatesTime: January 15th, 9:30 am

Kelun Biotech focuses on major disease areas such as oncology, autoimmune disorders, inflammation, and metabolism.According to the Insight database, Kelun-Biotech currentlyThree new drugs have been approved for marketing, respectivelyTagolimab（PD-L1 Monoclonal Antibody）、Lukang Satuzumab（TROP2 ADC）AndBoductuzumab（HER2 ADC）. In addition, there is 1 more.Lenvatinib（RET Inhibitor）Submitted for marketing approval.

Screenshot source: Insight database

In 2025, Kelun-Biotech respectivelyHBM9378（TSLP Monoclonal Antibody）AndSKB105（ITGB6 ADC）Reached significant collaborations with Windward Bio and Crescent Biopharma, expanding the international cooperation dimensions in the field of oncology treatment; additionally, Kelun Biotech has also successfully completedAbout$250 millionNew share placement injects strong support for R&D innovation.

Company Name:China Biopharmaceuticals

Speech Time:Pacific Ocean, United StatesTime: January 15, 10:00 am

China Biologic Products Holdings includes companies such as Chia Tai Tianqing, Tede Pharmaceutical, Nanjing Chia Tai Tianqing, and Limin Pharmaceuticals, etc.Focusing on innovative R&D in core areas such as oncology, hepatology, respiratory, and surgery/pain management, the first half of 2025Innovative Product RevenueUp to 7.8 billion yuan,Accounting for 44.4% of total revenue.

Insight database shows that, in 2025, China Biopharmaceutical has reached5 Medical DealsAmong them, the acquisition deal with Lixun Pharmaceuticals in July not only fired the first shot of domestic innovation drug acquisitions but also further strengthened its R&D capabilities in cutting-edge molecular types and tumor immunology.

Screenshot source:Insight Database

Company Name:Hengrui Medicine

Speech Time:Pacific Ocean, United StatesTime: January 15, 10:30 am

Hengrui Medicine focuses on the research and development of new drugs in the fields of oncology, metabolism and cardiovascular diseases, immunology and respiratory diseases, as well as neuroscience. According to the Insight database,Hengrui's new drugs currently under research haveMore Than 300 Products，Among them, the approved innovative drugs include27 Products, innovative drugs in the status of marketing application include5 items。

Screenshot source:Insight Database

Driven by the continuous growth of innovative drugs and the steady increase in BD revenue, Hengrui 2025Revenue for the first three quarters reachedRMB 23.188 billion, a year-on-year increase of 14.85%, with net profit surging by 24.5% to reach 5.751 billion yuan.In addition, Hengrui successfully landed on the Hong Kong stock market in 2025.Becoming another "A+H" dual-listed company.

Company Name: Baili Tianheng

Speech Time:Pacific Ocean, United StatesTime: January 15, 11:30 am

BeOne MedicinesIn the field of macromolecular therapy for tumors（ADC/GNC/ARC）With globally leading innovative R&D capabilities, global clinical development, and large-scale production and supply capabilities,Committed to becoming a globally leading MNC in the field of cancer treatment.

According to the Insight database, BeOne Medicines has a new drug currently in the application stage for market approval.A global firstEGFR/HER3 Bispecific Antibody ADCDrug Iza-bren. In addition, BeOne Medicines has 18 new drugs entering the clinical stage, including BL-M07D1（HER2 ADC）、 Izalontamab（EGFR/HER3 Bispecific Antibody）、BL-M11D1（CD33 ADC）etc.

Screenshot source: Insight database

In addition to the pharmaceutical companies introduced above, Henlius, Bowang Pharmaceutical, and Antengene will also participate in this year's JPM conference. Furthermore, CRO companies such as the Wuxi group (Wuxi AppTec, Wuxi Biologics, Wuxi XDC) and Tigermed will also appear at this year’s JPM conference. Due to space limitations, these companies will not be individually introduced in this article.

Insight database will continue to track the progress of this year's JPM conference and provide the latest information on innovative drug development.

Cover Source:Zhan Kou Hai Luo

Disclaimer:This article is for information sharing only and does not represent the position or viewpoint of Insight. It does not recommend or introduce any treatment plans. If necessary, please consult and contact正规医疗机构.

Editor: Xi

PR Article Coordination: WeChat insightxb

SubmissionWeChat: insightxb; Email: insight@dxy.cn